ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.98
0.02%
US Tech 100
20,910.00
1.14%
S&P 500
6,086.49
0.61%
US Dollar vs CAD
1.40735
0.05%
Bitcoin
98,675.14
2.82%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Akcea Therapeutics Inc (AKCA) Share Price

Akcea Therapeutics Inc

Akcea Therapeutics Inc (AKCA)

NASDAQ
18.17
0.00
(0.00%)
At close: December 04 3:00PM
Delayed by 15 minutes
18.17
0.00
( 0.00% )
After Hours: -
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
18.17
Bid
18.08
Ask
19.00
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
18.17
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

Ask ADVFN Intelligence (AI)

AKCA Latest News

More News

Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product

Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif., Oct...

October 30 2020
PR Newswire (US)

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics

Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif., Oct. 12...

October 12 2020
PR Newswire (US)

WAYLIVRA▼® (volanesorsen), the First & Only Therapy for FCS, an Ultra-Rare & Life-Threatening Condition, to Be Available o...

National Institute for Health and Care Excellence (NICE) issues a positive recommendation for volanesorsen to treat adults with Familial Chylomicronaemia Syndrome (FCS) Akcea Therapeutics UK...

September 18 2020
Business Wire

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics - Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash - Transaction...

August 31 2020
PR Newswire (US)

Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020

Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant...

August 29 2020
PR Newswire (US)

Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020

Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020 Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent...

August 29 2020
PR Newswire (US)

Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020

Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020 Late-breaking presentation to focus on efficacy and safety data of vupanorsen in...

August 24 2020
PR Newswire (US)

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020

Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020 Data presentation will highlight efficacy, safety and tolerability of...

August 18 2020
PR Newswire (US)

Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany

Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in...

August 13 2020
PR Newswire (US)

Akcea Reports Financial Results and Highlights for Second Quarter 2020

Akcea Reports Financial Results and Highlights for Second Quarter 2020 Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year Achieved Pricing and Reimbursement Across Key...

August 04 2020
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIGIMawson Infrastructure Group Inc
US$ 1.07
(57.33%)
6.48M
PRFXPainReform Ltd
US$ 4.02
(50.00%)
3.77M
VRNTVerint Systems Inc
US$ 30.75
(18.41%)
335.37k
REVBRevelation Biosciences Inc
US$ 0.551
(17.28%)
1.23M
PBMPsyence Biomedical Ltd
US$ 2.83
(12.30%)
3.82k
BLUEbluebird bio Inc
US$ 0.4399
(-40.26%)
12.75M
UPXIUpexi Inc
US$ 4.40
(-26.30%)
97.52k
HTOOFusion Fuel Green PLC
US$ 0.4383
(-15.71%)
709.36k
CYCNCyclerion Therapeutics Inc
US$ 5.37
(-15.43%)
1.04M
PEVPhoenix Motor Inc
US$ 0.3206
(-12.98%)
9.55M
LCIDLucid Group Inc
US$ 2.10
(0.00%)
31.66M
BLUEbluebird bio Inc
US$ 0.4399
(-40.26%)
12.75M
PEVPhoenix Motor Inc
US$ 0.3206
(-12.98%)
9.55M
SMXSMX Security Matters Public Company
US$ 0.39
(-2.50%)
8.2M
MIGIMawson Infrastructure Group Inc
US$ 1.07
(57.33%)
6.48M

AKCA Discussion

View Posts
Sidney Sidney 7 years ago
Any thoughts on why so low today?
👍️0
Thoro Thoro 7 years ago
So Volatile. Any thoughts on why the big plunge today?
👍️0
Rodney213 Rodney213 7 years ago
Like how clean the board is .Some heavy price target coverage today
👍️0
dinosaurbob dinosaurbob 7 years ago
Dropped heavy yesterday but bounced back some today. I am still up 17%, so I am not complaining.
👍️0
Thoro Thoro 7 years ago
This is a volatile stock. Its finding its legs.
👍️0
dinosaurbob dinosaurbob 7 years ago
Closed at $15.43 today up 47 cents.
👍️0
dinosaurbob dinosaurbob 7 years ago
Back up $1.02 today. This stock is like riding a roller coaster. Up one day and down the next. And big drops and rises too.
👍️0
dinosaurbob dinosaurbob 7 years ago
WTH happened today? Down $1.52!
👍️0
dinosaurbob dinosaurbob 7 years ago
Closed up 40 cents at $14.88
👍️0
dinosaurbob dinosaurbob 7 years ago
It was up big earlier but steadily dropping now. Still up 14 cents at 2:45 EST
👍️0
Thoro Thoro 7 years ago
AKCA, Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency

https://ih.advfn.com/p.php?pid=nmona&article=75321782
👍️0
dinosaurbob dinosaurbob 7 years ago
Closed up at $14.48 (5.16%). Nice!
👍️0
Thoro Thoro 7 years ago
I know it dropped, but I like when it tests higher.
👍️0
dinosaurbob dinosaurbob 7 years ago
Yes, but it dropped to $13.77. I still believe in it though.
👍️0
Thoro Thoro 7 years ago
AKCA $16.30 looked great today!
👍️0
dinosaurbob dinosaurbob 7 years ago
I bought in at 9.88 and then doubled my portfolio Friday at $13.00. I see this over $20.00 by October!
👍️0
Thoro Thoro 7 years ago
AKCA

IPO doing great first 5 days of trading.
👍️0
Thoro Thoro 7 years ago
AKCA

#MARKET NEWS
JULY 14, 2017 / 12:12 PM / 3 DAYS AGO
BRIEF-Akcea Therapeutics Inc shares open at $8.13 in debut vs IPO price of $8/share

http://www.reuters.com/article/brief-akcea-therapeutics-inc-shares-open-idUSFWN1K50CZ




👍️0
Thoro Thoro 7 years ago
AKCA

#MARKET NEWS
JULY 13, 2017 / 8:30 PM / 4 DAYS AGO

BRIEF-Akcea Therapeutics says public offering of 15.6 mln common shares priced at $8 per share

http://www.reuters.com/article/brief-akcea-therapeutics-says-public-off-idUSASA09X2O

👍️0

Your Recent History

NASDAQ
AKCA
Akcea Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved